315 related articles for article (PubMed ID: 30063847)
1. Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy.
Danielli R; Cisternino F; Giannarelli D; Calabrò L; Camerini R; Savelli V; Bova G; Dragonetti R; Di Giacomo AM; Altomonte M; Maio M
Expert Opin Biol Ther; 2018 Jul; 18(sup1):77-83. PubMed ID: 30063847
[TBL] [Abstract][Full Text] [Related]
2. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
3. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
Maio M; Mackiewicz A; Testori A; Trefzer U; Ferraresi V; Jassem J; Garbe C; Lesimple T; Guillot B; Gascon P; Gilde K; Camerini R; Cognetti F;
J Clin Oncol; 2010 Apr; 28(10):1780-7. PubMed ID: 20194853
[TBL] [Abstract][Full Text] [Related]
4. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
[No Abstract] [Full Text] [Related]
5. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
Callahan MK; Kluger H; Postow MA; Segal NH; Lesokhin A; Atkins MB; Kirkwood JM; Krishnan S; Bhore R; Horak C; Wolchok JD; Sznol M
J Clin Oncol; 2018 Feb; 36(4):391-398. PubMed ID: 29040030
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.
Yamazaki N; Uhara H; Fukushima S; Uchi H; Shibagaki N; Kiyohara Y; Tsutsumida A; Namikawa K; Okuyama R; Otsuka Y; Tokudome T
Cancer Chemother Pharmacol; 2015 Nov; 76(5):969-75. PubMed ID: 26407818
[TBL] [Abstract][Full Text] [Related]
8. Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study.
Dalle S; Mortier L; Corrie P; Lotem M; Board R; Arance AM; Meiss F; Terheyden P; Gutzmer R; Buysse B; Oh K; Brokaw J; Le TK; Mathias SD; Scotto J; Lord-Bessen J; Moshyk A; Kotapati S; Middleton MR
BMC Cancer; 2021 May; 21(1):642. PubMed ID: 34051732
[TBL] [Abstract][Full Text] [Related]
9. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
Larkin J; Minor D; D'Angelo S; Neyns B; Smylie M; Miller WH; Gutzmer R; Linette G; Chmielowski B; Lao CD; Lorigan P; Grossmann K; Hassel JC; Sznol M; Daud A; Sosman J; Khushalani N; Schadendorf D; Hoeller C; Walker D; Kong G; Horak C; Weber J
J Clin Oncol; 2018 Feb; 36(4):383-390. PubMed ID: 28671856
[TBL] [Abstract][Full Text] [Related]
10. Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient.
Mandalà M; Merelli B; Indriolo A; Tondini C
Eur J Cancer; 2018 May; 95():130-132. PubMed ID: 29559189
[No Abstract] [Full Text] [Related]
11. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
12. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.
Yun S; Vincelette ND; Green MR; Wahner Hendrickson AE; Abraham I
Cancer Med; 2016 Jul; 5(7):1481-91. PubMed ID: 27167347
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival with modern therapeutic agents against metastatic melanoma-vemurafenib and ipilimumab in a daily life setting.
Lang BM; Peveling-Oberhag A; Faidt D; Hötker AM; Weyer-Elberich V; Grabbe S; Loquai C
Med Oncol; 2018 Jan; 35(3):24. PubMed ID: 29387968
[TBL] [Abstract][Full Text] [Related]
14. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.
Prieto PA; Yang JC; Sherry RM; Hughes MS; Kammula US; White DE; Levy CL; Rosenberg SA; Phan GQ
Clin Cancer Res; 2012 Apr; 18(7):2039-47. PubMed ID: 22271879
[TBL] [Abstract][Full Text] [Related]
15. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
[TBL] [Abstract][Full Text] [Related]
16. Metastatic melanoma: a regional review and future directions.
Khan KH; Goody RB; Hameed H; Jalil A; Coyle VM; McAleer JJ
Tumori; 2012; 98(5):575-80. PubMed ID: 23235751
[TBL] [Abstract][Full Text] [Related]
17. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.
Ascierto PA; Del Vecchio M; Mackiewicz A; Robert C; Chiarion-Sileni V; Arance A; Lebbé C; Svane IM; McNeil C; Rutkowski P; Loquai C; Mortier L; Hamid O; Bastholt L; Dreno B; Schadendorf D; Garbe C; Nyakas M; Grob JJ; Thomas L; Liszkay G; Smylie M; Hoeller C; Ferraresi V; Grange F; Gutzmer R; Pikiel J; Hosein F; Simsek B; Maio M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503946
[TBL] [Abstract][Full Text] [Related]
18. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM
Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816
[TBL] [Abstract][Full Text] [Related]
19. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
Di Giacomo AM; Ascierto PA; Queirolo P; Pilla L; Ridolfi R; Santinami M; Testori A; Simeone E; Guidoboni M; Maurichi A; Orgiano L; Spadola G; Del Vecchio M; Danielli R; Calabrò L; Annesi D; Giannarelli D; Maccalli C; Fonsatti E; Parmiani G; Maio M
Ann Oncol; 2015 Apr; 26(4):798-803. PubMed ID: 25538176
[TBL] [Abstract][Full Text] [Related]
20. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE
Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
